Singapore markets closed
Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,286.99 +9.48 (+0.18%) Dow
38,618.62 -67.70 (-0.17%) Nasdaq
16,835.70 +100.69 (+0.60%) Bitcoin USD
69,692.98 +1,579.05 (+2.32%) CMC Crypto 200
1,506.09 +38.15 (+2.60%)
C4 Therapeutics, Inc. (CCCC)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:05AM EDT. Market open.
| Previous close | 5.0000 |
| Open | 5.0000 |
| Bid | 4.9800 x 100 |
| Ask | 5.0700 x 100 |
| Day's range | 4.9200 - 5.0300 |
| 52-week range | 1.0600 - 11.8800 |
| Volume | |
| Avg. volume | 1,709,403 |
| Market cap | 343.341M |
| Beta (5Y monthly) | 3.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.3700 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.86 |
Simply Wall St.We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GuruFocus.com
C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations
Performance Analysis and Future Outlook Amidst Financial Adjustments
GlobeNewswireC4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 0
© 2024 Yahoo. All rights reserved.